gamma-aminobutyric acid type A receptor subunit alpha5Genealiases: DEE79 · EIEE79
Q-omics provides the consensus-scored GABRA5 profile across patient tissues and cancer cell-line models. GABRA5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GABRA5 is differentially expressed in 9, with the highest sampling consensus in STAD. Additionally, GABRA5 RNA expression shows 15,728 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, STAD, and GBM as cancer lineages where GABRA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GABRA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GABRA5 survival associations across molecular data types. GABRA5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GABRA5 RNA expression–survival associations across cancer types. High GABRA5 expression shows unfavorable associations in UVM, SKCM, UCEC, LUAD and KIRP, but favorable associations in PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GABRA5 RNA expression.
This table summarizes GABRA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GABRA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GABRA5 shows lower tumor expression in STAD, THCA and KIRC and higher tumor expression in BRCA, LUSC and LUAD. The STAD box plot shows higher GABRA5 RNA expression in normal versus tumor tissue (log2 FC = −0.675, t-test p = .001).
This table shows molecular features associated with GABRA5 in patient tissues and cancer cell lines. In patient samples, GABRA5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GABRA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SKIN.
